Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07123701) titled 'Clinical Study of Tanshinone Capsules Against COVID-19' on Aug. 11.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Liu Shuwen
Condition:
COVID-19 (Coronavirus Disease 2019)
Intervention:
Drug: Tanshinone capsules
Recruitment Status: Not recruiting
Phase: Phase 2/Phase 3
Date of First Enrollment: March 1, 2024
Target Sample Size: 80
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07123701
Published by HT Digital Content Services wit...